Carbonato de lantano
Lanthanum Carbonate
Lanthanum carbonate (octa-hydrate)
También conocido como: Fosrenol · Lantharenol · Renalzin · Bay-78-1887 · Lanthanum
Revisado por el equipo veterinario de VetSheetActualizado 5 abr 2026Referencia veterinaria basada en la evidencia
Las dosis son una referencia clínica para profesionales veterinarios autorizados. Confirme siempre con el prospecto actual y cada paciente individual.
Dosis por especie
🌎 NA — North America🌍 EU — Europe
Perros
| Indicación | Dosis | Vía | Frecuencia | Duración | Región |
|---|---|---|---|---|---|
| Chronic kidney disease (Hyperphosphataemia) | 100 mg/kg/day | PO | divided between meals | Chronic | 🌍 EU |
- Chronic kidney disease (Hyperphosphataemia): Dose adjustments should be based on serum phosphate levels monitored at 4-6 week intervals.
Gatos
| Indicación | Dosis | Vía | Frecuencia | Duración | Región |
|---|---|---|---|---|---|
| Phosphate binder | 200 mg (total dose) PO (on/in food) 2-3 times daily. | PO | 2-3 times daily | — | 🌎 NA |
| Phosphate binder (using Renalzin) | 2 mLs (400 mg) applied in the cat's food, once or twice daily depending on the cat's feeding regimen. | PO | once or twice daily | — | 🌎 NA |
| Chronic kidney disease (Hyperphosphataemia) | 400-800 mg/cat/day | PO | divided according to feeding schedule (give some with every meal) | Chronic | 🌍 EU |
- Phosphate binder: Anecdotally appears safe and effective.
- Chronic kidney disease (Hyperphosphataemia): Recommended starting dose is 400 mg per day. It is important to give some with every meal.
Las dosis son una referencia clínica para profesionales veterinarios autorizados. Confirme siempre con el prospecto actual y cada paciente individual.
Resumen
El carbonato de lantano es un agente quelante de fosfato de administración oral utilizado principalmente para el manejo de la hiperfosfatemia en pacientes con enfermedad renal terminal (ERT).
Si bien la restricción dietética de fósforo sigue siendo la piedra angular del manejo de la enfermedad renal crónica (ERC), los quelantes de fosfato están indicados cuando la dieta por sí sola es insuficiente o rechazada por el paciente.
Perla clínica: A diferencia de los quelantes basados en calcio (que pueden causar hipercalcemia) o los basados en aluminio (que conllevan un riesgo de toxicidad por aluminio con el uso a largo plazo), el lantano es un quelante no cálcico y no alumínico, lo que lo convierte en una opción atractiva para el manejo crónico de la hiperfosfatemia en pacientes veterinarios.
Mecanismo de acción
Lanthanum carbonate acts locally in the gastrointestinal tract.
- It dissociates in the acidic environment of the upper GI tract (stomach) to release lanthanum ions (La³⁺).
- These ions bind to dietary phosphate → forming highly insoluble lanthanum phosphate complexes.
- These complexes cannot cross the intestinal mucosa and are subsequently eliminated in the feces, thereby reducing net intestinal absorption of phosphorus.
Seguridad y advertencias
Contraindicaciones
- Patients with non-intact GI tract (e.g., GI ulcers, colitis) - use with caution due to increased risk of systemic absorption
- Acute renal crisis (patients should be stabilized first)
Efectos adversos
- Inappetence
- None known according to the monograph
- Gastrointestinal upset (nausea, vomiting, diarrhea, or constipation) may occur (Clinical Pearl)
Precauciones
There are no listed absolute contraindications, but it should be used with caution in patients where the GI tract is not intact (e.g., GI ulcers, colitis) as there is an increased chance for oral absorption. Safe for use during pregnancy and nursing.
Interacciones farmacológicas
Potential decreased absorption; separate dosing by 2 hours
Potential decreased absorption; separate dosing by 2 hours
Potential decreased absorption; separate dosing by 2 hours
Potential decreased absorption; separate dosing by 2 hours
Potential decreased absorption; separate dosing by 2 hours
Potential decreased absorption; separate dosing by 2 hours
Potential decreased absorption; separate dosing by 2 hours
Potential decreased absorption; separate dosing by 2 hours
Potential decreased absorption; separate dosing by 2 hours
Potential decreased absorption; separate dosing by 2 hours
Potential decreased absorption; separate dosing by 2 hours
Potential decreased absorption; separate dosing by 2 hours
Potential decreased absorption; separate dosing by 2 hours
Lanthanum may bind to other drugs in the GI tract, reducing their absorption. Should be given at least 1 hour before or 3 hours after other medications.
Monitorización
- Serum phosphorous
- Serum potassium
- Serum bicarbonate
- Serum chloride
- Serum phosphate levels (at 4-6 week intervals to adjust dosage and achieve target concentrations)
- Renal parameters (BUN, Creatinine, SDMA)
- Serum calcium levels
Farmacocinética
Vida media
Absorción
Following oral doses, lanthanum bioavailability is very low (less than 0.002%).
Distribución
Systemically available lanthanum is very highly bound to plasma proteins (>99%). Tissue levels increase over time and can be several orders of magnitude higher than plasma levels. Highest levels found in GI tract, bone, and liver.
Metabolismo
Not metabolized. It is an inorganic salt.
Eliminación
Absorbed lanthanum is cleared primarily via biliary excretion into the feces. In dogs, mean recovery of an oral dose averages 94%.
Sobredosis
No specific information located, but acute overdose is likely tolerated with potential for GI effects. Only supportive treatment should be required. In cats, oral dosages up to 1 gram/kg were tolerated, but repeated vomiting occurred at 2 grams/kg.
Productos disponibles
Formulaciones
- Chewable tablets
- Pump gel/paste
- 500 mg chewable tablet
- 750 mg chewable tablet
- 1 g chewable tablet
Veterinario
- Renalzin (lanthanum carbonate, kaolin, vitamin E) pump gel/paste (200 mg/mL) - Available in some countries outside USA/Canada
- Lantharenol (General sale / Feed additive - availability varies)
Etiquetado para humanos
- Fosrenol Oral Chewable Tablet 500 mg, 750 mg, & 1,000 mg
- Fosrenol 500 mg chewable tablets
- Fosrenol 750 mg chewable tablets
- Fosrenol 1 g chewable tablets
Estado regulador
Fosrenol is POM; Lantharenol has been marketed as a general sale feed additive.
Fosrenol is POM; Lantharenol has been marketed as a general sale feed additive.
Sin datos reguladores para: 🇺🇸 US · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
Almacenamiento y estabilidad
Store tablets at room temperature (25°C, 77°F); excursions are permitted to 15°-30°C (59°-86°F). Protect from moisture.
Información para el cliente
- Administración: No permita que el animal trague los comprimidos enteros. Tritúrelos y mézclelos bien con la comida del animal.
- Momento de la administración: Es fundamental que este medicamento se administre con las comidas para que pueda unirse al fósforo presente en el alimento.
- Productos veterinarios comerciales: Si utiliza un gel o pasta veterinaria específica, siga las instrucciones de administración exactas proporcionadas en la etiqueta.
- Efectos secundarios: Vigile si presenta vómitos o pérdida de apetito y contacte a su veterinario si estos ocurren.
La referencia de medicamentos de VetSheet está destinada a profesionales veterinarios autorizados como ayuda para la toma de decisiones clínicas, no como sustituto del criterio profesional ni del prospecto actual del fabricante.